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Abstract
Background
This retrospective, multicenter study aimed to reveal risk predictors for mortality in the inten-
sive care unit (ICU) as well as survival after ICU discharge in patients with acute myeloid
leukemia (AML) requiring treatment in the ICU.
Methods and Results
Multivariate analysis of data for 187 adults with AML treated in the ICU in one institution
revealed the following as independent prognostic factors for death in the ICU: arterial oxy-
gen partial pressure below 72 mmHg, active AML and systemic inflammatory response syn-
drome upon ICU admission, and need for hemodialysis and mechanical ventilation in the
ICU. Based on these variables, we developed an ICU mortality score and validated the
score in an independent cohort of 264 patients treated in the ICU in three additional tertiary
hospitals. Compared with the Simplified Acute Physiology Score (SAPS) II, the Logistic
Organ Dysfunction (LOD) score, and the Sequential Organ Failure Assessment (SOFA)
score, our score yielded a better prediction of ICU mortality in the receiver operator
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characteristics (ROC) analysis (AUC = 0.913 vs. AUC = 0.710 [SAPS II], AUC = 0.708
[LOD], and 0.770 [SOFA] in the training cohort; AUC = 0.841 for the developed score vs.
AUC = 0.730 [SAPSII], AUC = 0.773 [LOD], and 0.783 [SOFA] in the validation cohort). Fac-
tors predicting decreased survival after ICU discharge were as follows: relapse or refractory
disease, previous allogeneic stem cell transplantation, time between hospital admission
and ICU admission, time spent in ICU, impaired diuresis, Glasgow Coma Scale <8 and
hematocrit of25% at ICU admission. Based on these factors, an ICU survival score was
created and used for risk stratification into three risk groups. This stratification discriminated
distinct survival rates after ICU discharge.
Conclusions
Our data emphasize that although individual risks differ widely depending on the patient
and disease status, a substantial portion of critically ill patients with AML benefit from inten-
sive care.
Introduction
AML is the most common type of acute leukemia in adults, accounting for approximately 2.8%
of all cancer worldwide [1]. Without treatment, AML is fatal, but therapy and prognosis have
improved in recent decades [2]. Intensive chemotherapy, either alone or followed by autolo-
gous or allogeneic stem cell transplantation, has the potential to cure AML, and long-term sur-
vival of patients is increasing [3]. However, such intensive treatment is associated with
potentially life-threatening toxicities, particularly in elderly patients. Although decision tools
might aid decisions regarding which elderly patients are amenable to intensive treatment [4,5],
approximately 13% of patients with AML require ICU treatment [6]. Several studies have
described clinical outcomes and prognostic factors for patients with or without other hemato-
logical malignancies. The majority of these studies are of limited value because they were based
on small cohorts, not validated in an independent cohort, included unselected patients with
solid cancer and hematological malignancies, did not distinguish between ICU and hospital
mortality, did not analyze survival and/or were solely focused on complications [6–16].
The decision to admit a patient to the ICU is often an ethical dilemma and is based on the
individual clinician’s decision, which is loosely based on established scores (e.g., SOFA, LOD,
APACHE II, SAPS II) [17–20]. Because these scores are based on and designed for analysis of
unselected patients admitted to the ICU, patients with cancer, particularly those with AML, are
underrepresented. For example, APACHE II and SAPS II consider malignancy as a risk factor
without further differentiation of the type or disease status of the malignancy. APACHE II con-
siders only five points for immunocompromised, non-operative patients, while allowing a total
range between 0 and 71.
The objective of this study was to establish and validate risk factors associated with mortality
during and after ICU treatment based on a large and multicenter cohort and to establish poten-
tial risk scores.
Materials and Methods
Patients and treatment
The AML in ICU score was established in a cohort of 187 adults with AML admitted to the
ICU at the University Hospital of Muenster, representing all patients with a diagnosis of AML
admitted to the ICU between 11/2004 and 09/2011. Data were collected retrospectively from
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patient records and follow-up physicians. Prior to analysis, the data were anonymized and de-
identified. Approval for this investigation was obtained from the Ethics Board of Westfalian
Wilhelms-University Muenster and the Physicians Chamber of Westfalia-Lippe, Germany
(2015-688-f-S).
Validation was performed on a cohort of 264 patients with AML admitted to the ICU at the
University Hospital of Grosshadern in Munich, the University Hospital of Cologne and the
Municipal Hospital of Augsburg (all located in Germany) between 01/2004 and 02/2010.
Intensive induction treatment consisted of any of the following: “7+3” (cytarabine 100 mg/
m² once daily on days 1–7 as a 24-h intravenous infusion and daunorubicin 45 mg/m² once
daily on days 3–5, intravenous infusion; “7+GO” (cytarabine 100 mg/m² once daily on days
1–7 as a 24-h intravenous infusion and gemtuzumab ozogamicin 6 mg/m² once on day 1 and 4
mg/m² once on day 8, intravenous infusion); “TAD” (tioguanine 100 mg/m² twice per day on
days 3–9, orally; cytarabine 100 mg/m² on days 1–2 as an intravenous infusion and 100 mg/m²
twice daily on days 3–8, intravenous infusion; and daunorubicin 60 mg/m² once daily on days
3–5, intravenous infusion); “HAM” (high-dose cytarabine 3 g/m² twice daily on days 1–3,
intravenous infusion, and mitoxantrone 10 mg/m² once daily on days 3–5, intravenous infu-
sion; patients>60 years of age received only 1g/m² cytarabine); and “S-HAM” (high-dose
cytarabine 3g/m² twice daily on days 1–2 and 8–9, intravenous infusion, and mitoxantrone 10
mg/m² once daily on days 3–4 and 10–11, intravenous infusion; patients>60 years of age
received 1 g/m² cytarabine). With the exception of dose-dense S-HAM induction, patients<60
years of age routinely received two induction courses, whereas patients aged 60+ received a sec-
ond induction course only in case of persisting bone marrow blasts on day 15 after the start of
treatment. Postremission treatment consisted of high-dose cytarabine in case of “7+3” or “7
+GO” induction (patients<60 years received three courses of cytarabine 3g/m² twice daily on
days 1, 3 and 5, intravenous infusion; those 60 years or older only received two courses of cytar-
abine 3g/m² twice daily on days 1, 3 and 5, intravenous infusion). Postremission treatment also
consisted of TAD consolidation followed by prolonged monthly maintenance therapy in case
of “TAD(-HAM)”, “HAM(-HAM)” or “S-HAM” induction or was followed by autologous
SCT in younger patients. Details of the treatment protocols have been published elsewhere
[21–23]. According to the patient’s risk of relapse, allogeneic stem cell transplantation was per-
formed alternatively to the scheduled postremission treatment in patients in first remission or
after relapse when possible. Conditioning protocols varied and depended on the remission sta-
tus and age of the patients [24–26].
Only disease status was included in the analysis. Owing to the broad heterogeneity of the
applied protocols, a detailed analysis of chemotherapy regimen related to death in the ICU and
survival after ICU discharge could not reasonably be performed. (Re)induction protocols are
applied in active disease or at primary diagnosis, and consolidation regimens are administered
in cases of complete remission. Owing to this strong correlation, information about chemo-
therapy protocols is already included in the variable disease status.
Endpoints
Complete remission was defined as hematological recovery with at least 1,000 neutrophils
per μl, at least 100,000 platelets per μl, and< 5% bone marrow blasts. ICU mortality was
defined as death at any time during the course of the ICU stay. Overall survival after ICU dis-
charge was survival from the day of ICU discharge until death from any cause, and censoring
of patients known to be alive at the time of last follow-up was performed. The term mortality,
when given as a percentage, was defined as the number of deaths per number of ICU stays
observed.
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Definition of variables
Arterial oxygen partial pressure (paO2) was evaluated at the time of ICU admission, irrespec-
tive of oxygen supply. Active AML at the time of ICU admission included 1, patients with pri-
mary diagnosed AML; 2, patients with relapsed AML before or during reinduction therapy or
before evaluation of the remission status at the time of ICU admission; and 3, patients with per-
sisting disease after induction or reinduction therapy at the last evaluation of disease status pre-
ceding ICU admission. Advanced AML at the time of ICU discharge was defined as refractory
or relapsed AML status. Serve infections as reason for ICU admission required at least two of
the following criteria: temperature>38°C (100.4°F) or<36°C (96.8°F), tachycardia (>90
bpm), tachypnea>20/min or clinically proved infectious complications (like microbiologically
documented infection or radiographic signs of an infection). To avoid affections by the AML
and/or associated therapy, leukocyte count was not considered. Days until ICU admission were
the days between hospital admission and ICU admission. The Glasgow Coma Scale (GCS) was
applied as previously described [27]. The Simplified Acute Physiology Score (SAPS) II was rou-
tinely determined in all ICU patients [28]. Additionally, the LOD and SOFA score were calcu-
lated in the training cohort to enhance comparability to other ICU scores [19,20,29]. Variables
used for calculation of all scores were determined at the time of admission. As prothrombin
values were not available in most cases and to avoid potential bias, LOD was thoroughly calcu-
lated without prothrombin values. Cytogenetic and molecular genetic risk were classified
according to European LeukemiaNet (ELN) guidelines 2010 [30].
Statistical Analysis
Correlations with ICU mortality were evaluated using the Chi-square test for categorical data
and the Mann-Whitney U test for continuous variables. Only variables with less than 10%
missing values in the training cohort were considered. Missing values were replaced by the
median value of the variable. Continuous variables were categorized where appropriate (S1
Table). Variables with p<0.1 in the univariate evaluation were selected for a multivariate
binary logistic regression with stepwise backward selection and a threshold value of 0.05 for
inclusion and 0.1 for exclusion. The final model of the variable selection process was used as
the scoring model.
Survival analyses were performed by Kaplan Meier estimates. Correlations with survival
were evaluated by the log-rank test; parameters with p<0.1 in the log-rank test were evaluated
in multivariate Cox regression analysis with stepwise backward selection and a threshold value
of 0.05 for inclusion and 0.1 for exclusion. Unless otherwise stated, the significance level was
alpha = 0.05 in all analyses.
All statistical analyses were performed in cooperation with the Institute of Biostatistics and
Clinical Research of the University Hospital of Muenster, Germany, and were computed with
IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY).
Results
Patient characteristics
Patient characteristics are presented in Table 1. At the time of ICU admission, the median age
of the patients was 59 years. Compared with the training cohort, the validation cohort included
more patients with newly diagnosed AML and fewer patients in remission. The training cohort
also had lower paO2 and hematocrit at the time of ICU admission. Among patients surviving
the ICU, the median duration of treatment was three days in the validation cohort and four
days in the training cohort. Age and sex, the combined cytogenetic and molecular risk profile
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according to ELN2010 classification, the proportion of patients who had previously undergone
allogeneic stem cell transplantation, the reason for ICU admission, and the proportion of
patients requiring mechanical ventilation or dialysis in the ICU were distributed similarly
between the training and validation cohorts (Table 1). Information about type of AML (de
novo versus secondary), time interval between hospital admission and ICU admission, mean
arterial pressure at ICU admission, diuresis and GCS at the time of ICU admission were not
available for the validation cohort.
Table 1. Baseline characteristics of all patients and patients surviving the ICU stay in the training and validation cohorts.
Parameter All patients ICU survivors
Training
cohort
Validation
cohort
p Training
cohort
Validation
cohort
p
No of patients / no of ICU stays 187 / 187 264 / 363 79 / 79 175 / 232
Age in years, median (range) 59 (16–83) 58 (17–85) 0.335 58 (16–83) 58 (20–85) 0.797
Male sex, n (%) 112 (60) 141 (53) 0.172 42 (53) 88 (50) 0.671
Type of AML, n (%)
de novo 136 (73) n.a. 58 (73) n.a.
Secondary AML 51 (27) n.a. 21 (27) n.a.
ELN 2010 risk classiﬁcation, n (%) 0.796 0.968
Low risk 33 (18) 45 (21) 19 (24) 33 (22)
Intermediate-I 81 (43) 91 (43) 30 (38) 61 (41)
Intermediate-II 17 (9) 18 (9) 7 (9) 14 (9)
High risk 56 (30) 57 (27) 23 (29) 41 (28)
Disease status at ICU admission, n (%) <0.001 <0.001
Newly diagnosed / not yet evaluated 78 (42) 194 (53) 26 (33) 136 (59)
In remission 63 (34) 68 (19) 33 (42) 37 (16)
Relapsed or refractory 46 (25) 101 (28) 20 (25) 59 (25)
Previous allogeneic SCT, n (%) 56 (30) 98 (27) 0.466 20 (25) 48 (21) 0.390
Reason for ICU admission, n (%) 0.189 0.047
Severe infection 95 (51) 163 (45) 19 (24) 84 (36)
Temperature > 38°C (100.4°F) or < 36°C (96.8°F) 63 (66) 81 (49) 9 (47) 39 (46)
Tachycardia (> 90 bpm) 80 (84) 127 (77) 12 (63) 53 (60)
Tachypnea > 20 /min 67 (71) 93 (57) 9 (47) 49 (58)
Microbiological ﬁndings 40 (42) 69 (42) 7 (36) 29 (34)
other reasons 92 (49) 200 (55) 60 (76) 148 (64)
Time between hospital admission and ICU admission in days,
median (range)
12 (0–90) n.a. 14 (0–43) n.a.
Time spent in ICU in days, median (range) n.e. n.e. 4 (0–65) 3 (0–66) 0.021
paO2 in mmHg, median (range) 76.5 (32–217) 82 (40–426) 0.042 80 (41.5–160) 84 (40–426) 0.502
Mean arterial pressure (MAP) in mmHg, median (range) 85 (40–155) n.a. 85 (40–130)
Hematocrit in %, median (range) 25 (13–44) 27 (18–44) <0.001 24 (13–43) 28 (18–44) <0.001
Urine production in l/24h, median (range) 1.45 (0–8.5) n.a. 1.9 (0.1–8.4) n.a.
Glasgow Coma Scale (GCS), median (range) 15 (3–15) n.a. 10 (3–15) n.a.
Patients with invasive ventilation, n (%) 110 (59) 179 (53) 0.162 24 (30) 63 (29) 0.858
Patients with hemodialysis on ICU, n (%) 58 (31) 88 (25) 0.120 8 (10) 29 (9) 0.828
Comparisons (Mann-Whitney U test for continuous variables and Chi-square test for categorized variables) were performed between the learning and
validation cohorts. Patient-speciﬁc variables (age, sex, ELN2010 risk classiﬁcation) were calculated according to the number of patients in the validation
cohort, whereas situation-speciﬁc variables (disease status, previous allogeneic transplantation, reason for ICU admission, duration of ICU stay, paO2 at
ICU admission, hematocrit at ICU admission, mechanical ventilation and hemodialysis on ICU) were calculated according to ICU stays.
Abbreviations: ELN, European LeukemiaNet; n.a., not available; n.e., not evaluated; paO2, arterial oxygen partial pressure; SCT, stem cell transplantation
doi:10.1371/journal.pone.0160871.t001
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Prognostic factors influencing ICU mortality
An overview of all parameters selected for analysis and their classification is presented in S1
Table.
Independent prognostic factors for ICU mortality in a multivariate model, displayed in Fig
1, were as follows: paO2<72 mmHg at ICU admission, active AML in the ICU (relapsed,
refractory, newly diagnosed), severe infection at ICU admission, and need for hemodialysis
and mechanical ventilation. On the basis of these five variables, a logistic model was generated
for the prediction of mortality in the ICU. The fitted logistic model is described by formulas 1
and 2, which can be used to calculate the predicted ICU mortality of each patient.
Formula 1:
X ¼ 3:921þ ð1:771 x hypoxemiaÞ þ ð1:200 x active AML on ICUÞ
þ ð2:175 x severe infectionÞ þ ð1:412 x hemodialysisÞ þ ð2:421 x mechanical ventilationÞ
Formula 2:
Predicted ICU mortality ¼ 1=½1þ expðXÞ
Coding of parameters used in formula 1:
Hypoxemia: paO2<72 mmHg at admission = 1; paO272 mmHg at admission = 0
Active AML on ICU: relapsed, refractory, newly diagnosed AML = 1; remission = 0
Severe infection: reason for ICU admission was infection with two of the following criteria
(temperature> 38°C or< 36°C, tachycardia> 90 bpm, or tachypnea> 20 /min) = 1; other
reason for ICU admission = 0
Hemodialysis: need for hemodialysis = 1; no need for hemodialysis = 0
Fig 1. Odds ratio (OR) plot of parameters associated with mortality in the ICU (intensive care unit).
Abbreviations: paO2, arterial oxygen partial pressure <72 mmHg at ICU admission.
doi:10.1371/journal.pone.0160871.g001
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Mechanical ventilation: need for mechanical ventilation = 1; no need for mechanical
ventilation = 0
Fig 2 shows the goodness of fit of the predicted ICU mortality as well as the SAPS II, the
LOD, and the SOFA score compared with the observed ICU mortality. Fig 2A presents the
receiver operator characteristics (ROC) analysis, and Fig 2B depicts a plot of the predicted ver-
sus observed mortality rates. The predicted ICU mortality had an AUC value of 0.913 (95% CI:
0.873–0.954), compared with an AUC of 0.721 (95% CI: 0.646–0.796) for the SAPSII Score in
the ROC of the training cohort (Fig 2A). The AUC analysis of the LOD and the SOFA score
showed similar values compares to the SAPS II Score (AUC = 0.708 [LOD] and 0.770 [SOFA]).
In patients with a predicted ICU mortality of<50% (median 18%, range 2–48%), 19% (15 of
81) died in the ICU (Fig 2B). By contrast, an ICU mortality of 88% (93 of 106) was observed in
the patients with a predicted ICU mortality of>50% (median 92%, range 51 to 99%) (Fig 2B).
When applying our score to the validation group, predicted ICU mortality had an AUC in
the ROC of 0.841 (95% CI: 0.784–0.897), compared with an AUC of 0.730 (95% CI: 0.661–
0.799) for the SAPSII Score, an AUC of 0.773 (95% CI: 0.696–0.851) for the LOD score, and
0.783 for the SOFA score (95% CI: 0.714–0.864)(Fig 3A). In quantitative terms, 16% (37 of
232) of patients with a predicted ICU mortality of<50% (median 18%, range 2–48%) died in
the ICU (Fig 3B). Consistent with the findings in the training cohort, the patients with a pre-
dicted ICU mortality of>50% (median 87%, range 66–99%) exhibited an increased mortality
rate of 72% (94 of 131) in the ICU (Fig 3B).
Prognostic factors for survival after ICU discharge
Seventy-nine patients (42%) in the training cohort survived their ICU stay. Table 1 displays the
characteristics of these ICU survivors. The projected 3-year survival of this cohort from the
time of ICU discharge was 64% (95% CI: 51–77%) after a median follow-up of 1.6 years. The
parameters selected for the analysis of association with prognosis after ICU discharge are also
listed in S1 Table. In multivariate Cox regression analysis, the following parameters were iden-
tified as independent prognostic factors for decreased survival after ICU discharge (Fig 4):
advanced disease (relapsed or refractory); previous allogeneic stem cell transplantation
(alloSCT); fewer days between hospital admission and ICU admission; more days spent in the
ICU; impaired diuresis<1,000 ml/24 hours at ICU admission; GCS<8 at ICU admission; and
a hematocrit of25% at ICU admission. Based on the Cox regression model, the risk score of
each patient was calculated using formula 2 and formula 3:
Formula 3:
X ¼ ð1:886 x advanced diseaseÞ þ ð0:974 x alloSCTÞ
þ ð0:036 x days in hospital before ICU admtextssionÞ  ð0:055 x days spent in ICUÞ
þ ð1:789 x decreased urine productionÞ
þ ð1:465 x decreased GCSÞ  ð1:510 x decreased hematocritÞ
Coding of parameters used in formula 3:
Advanced disease: relapsed or refractory = 1; newly diagnosed or in remission = 0
alloSCT: Previous alloSCT = 1; no history of alloSCT = 0
Days in hospital before ICU admission: Number of days between hospital admission and
ICU admission
Days spent in ICU: Number of days between ICU admission and ICU discharge
Decreased urine production: urine production<1,000 ml/24 hours at ICU admission = 1;
urine production>1,000 ml/24 hours at ICU admission = 0
Risk Prediction for AML Patients in Need of ICU
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Decreased GCS: GCS<8 at ICU admission = 1; GCS8 at ICU admission = 0
Decreased hematocrit: hematocrit of<25% at ICU admission = 1; hematocrit of25% at
ICU admission = 0
Stratifying the ICU survivors into three risk groups according to the risk score calculated
using formula 3 revealed marked differences in survival after ICU discharge. Patients with the
lowest risk (X values<0.23, n = 15) displayed one-year survival after ICU discharge of 100%.
Patients with intermediate risk (X values between 0.23 and 2.33, n = 34) exhibited 1-year sur-
vival of 82% (95% CI: 68–97%), and patients with the highest risk (X value>2.34, n = 30)
exhibited 1-year survival of 42% (95% CI: 22–63%) (Fig 5A).
Applying the same stratification to the validation group (median follow-up of 1.4 years)
revealed comparable differences in survival from the time of ICU discharge, although the sur-
vival rates were lower. One-year survival after ICU discharge was 69% (95% CI: 55–81%) in the
59 patients with the lowest risk, 51% (95% CI: 41–60%) in the group of 131 patients with inter-
mediate risk, and 19% (95% CI: 4–33%) in the 42 patients with high risk (Fig 5B).
Discussion
Despite encouraging survival rates of ICU survivors compared to non-ICU patients [31],
assumed high mortality represents a major reason for the widespread hesitation to refer AML
patients for treatment in the ICU. In addition, outcome prediction instruments are not valid in
individual patients, and ICU scoring systems are only capable of describing the severity of ill-
ness of ICU cohorts. The two most commonly used scores, SAPS II and APACHE II, were
established based on large numbers of unselected patients [18,28]. Because AML is rare in ICU
patients, patients with AML were clearly underrepresented in the establishment of these scores,
and both disease status and the impact of AML-specific procedures (such as an allogeneic stem
cell transplantation) were not considered in the design of global scoring systems, thus limiting
their applicability to patients with AML.
Sculier et al. published a report stating that neither SAPS II nor APACHE II are sufficiently
accurate to be used in the routine management of cancer patients requiring ICU treatment
[32]. They evaluated the prognostic value of these two scores for mortality both during the hos-
pital stay and after discharge in 261 cancer patients admitted to the ICU. No major difference
was observed between the two scoring systems, but outcome could not reliably be predicted.
Subgroup analyses of patients with hematological malignancies or patients with AML were not
performed in this study.
Based on the data for 451 patients with AML receiving available intensive care, the largest
cohort of AML patients analyzed to date, we were able to specifically analyze prognosis in this
defined patient population. Several risk predictors for ICU outcome as well as subsequent sur-
vival were identified, and we established a score predicting ICU mortality in patients with
AML. This score outperformed the established SAPS II, LOD, and SOFA scores in the training
and the validation cohort with respect to the area under the curve in the ROC analysis, regard-
less of hospital, treating physician, or treatment. Although the potential to discriminate was
Fig 2. Correlation of predicted versus actual ICUmortality (intensive care unit) in the training cohort.
(A) Receiver operator characteristics for the different scores with the area under the curve (AUC). Score 1:
novel mortality score. Score 2: SAPS II. Score 3: LOD. Score 4: SOFA. (B) Predicted versus actual ICU
mortality. Patients were classified according to their individual predicted ICU mortality (below versus50%;
boxes represent the interquartile range (IQR); whiskers indicate the minimum and maximum values but are
not longer than 1.5 times the length of the corresponding box; values outside this range are represented by
separate dots), which is plotted against the actual mortality rate for the three groups.
doi:10.1371/journal.pone.0160871.g002
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higher in the training cohort it was still evident in the validation cohort. The ability of our
score to accurately predict ICU mortality in this independent cohort supports the reliability of
the score. The results for patients with a low mortality risk may encourage clinicians to initiate
Fig 3. Correlation of predicted versus actual ICUmortality (intensive care unit) in the validation
cohort. (A) Receiver operator characteristics for the different scores with the area under the curve (AUC).
Score 1: novel score. Score 2: SAPS II. Score 3: LOD. Score 4: SOFA. (B) Predicted versus actual ICU
mortality. Patients were classified according to their individual predicted mortality in the ICU (below versus
50%; boxes represent the IQR; whiskers indicate the minimum and maximum values, but are not longer
than 1.5 times the length of the corresponding box; values outside this range are represented by separate
dots), which is plotted against the actual mortality rate.
doi:10.1371/journal.pone.0160871.g003
Risk Prediction for AML Patients in Need of ICU
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or extend intensive care to AML patients. However, the decision to pursue ICU treatment for
an AML patient requires an interdisciplinary approach that includes hematologists, intensive
care physicians, and consideration of the patients’ wishes and expectations. Thus, such a deci-
sion can never be based solely on the results of a score.
Originally all three scores, the SAPS II, LOD, and SOFA score, were generated on the basis
of the “worst” values in the first 24-hour period after admission[20,28,29]. To analyze their
applicability as a prognostic tool for the clinician, all scores in this manuscript are based on
data collected at the time of admission. This is an important difference to the preexisting scores
and underlines the relevance of the developed scores as prognostic tool in clinical use.
Previous studies have defined single parameters predicting ICU or hospital mortality in
cohorts including or comprising patients with AML, such as use of mechanical ventilation, low
fibrinogen [31], use of vasopressors [8,9], increased creatinine, number of failing organ systems
[8], illness severity [9], mechanical ventilation [13], sepsis, and length of hospital stay prior to
ICU admission [10]. Most of these factors were verified independently by our risk factor
analysis.
The mortality rate in the ICU was 58% in the training cohort and 36% in the validation
cohort. The reason for this discrepancy is unclear because the differences in the baseline char-
acteristics (Table 1) were not sufficient to provide an explanation. Admission criteria for ICU
patients vary from hospital to hospital. Nevertheless, these findings are comparable to recent
studies reporting mortality rates of 28–84% [6–9,15,31,33]. However, direct comparison with
published mortality rates is complicated by the use of different parameters: death in ICU, death
in hospital, or death after 90 days and/or one year.
In addition to predictors of ICU mortality, we also identified prognostic factors for ICU sur-
vival by AML patients. Not surprisingly, advanced disease status was a strong negative prog-
nostic factor for survival, and impaired immune responses to pathogens, particularly in the
Fig 4. Hazard ratio (HR) plot of parameters associated with survival after ICU (intensive care unit)
discharge. Abbreviations: SCT, stem cell/bone marrow transplantation; GCS, Glasgow Coma Scale; Hkt,
hematocrit.
doi:10.1371/journal.pone.0160871.g004
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early phase after allogeneic SCT, and severe acute and extensive chronic graft versus host dis-
ease are clearly associated with infectious complications [34].
Days spent in the hospital before ICU admission negatively influenced outcomes after ICU
discharge, whereas days spent in the ICU before ICU discharge had an opposite prognostic
influence on future survival. Azoulay et al. reported that fewer days in the hospital before ICU
admission was associated with improved hospital survival [7]. However, owing to the retro-
spective nature of this analysis and the possible presence of unknown confounding factors, a
recommendation for early admission to the ICU cannot be based on the present data.
Fig 5. Correlation of predicted survival rate after ICU (intensive care unit) discharge with overall
survival. Patients were grouped according to their probability of survival and the corresponding
Kaplan-Meier estimates. (A) Overall survival for patients in the training cohort. (B) Overall survival for
patients in the validation group.
doi:10.1371/journal.pone.0160871.g005
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Although a low hematocrit value does have a positive influence on the prognosis of ICU
patients [35], we identified low hematocrit at ICU admission as an independent risk factor for
survival after ICU stay but not for ICU mortality. Patients admitted to the ICU for infectious
complications benefit from a restrictive transfusion policy with tolerated hemoglobin values of
7.0 g/dl or below [36]. However, as stated above, our retrospective observation is insufficient to
recommend a restrictive transfusion policy with a hematocrit goal of<25%.
ELN low risk was significantly associated with survival after ICU discharge, whereas ELN
high risk exhibited only borderline significance. However, in contrast to the intention of ELN
risk classification, these cohorts do not represent homogeneous populations of patients with
untreated, newly diagnosed disease. The significant influences of disease status and previous
allotransplant on prognosis after ICU discharge suggest that ELN risk is diluted by disease
status.
Several limitations must be addressed. Our survival index distinguished three separate prog-
nostic groups in the test as well as in the validation cohort, but patient survival was inferior in
the validation cohort compared to the training cohort in every risk category. Missing values in
the validation cohort (days in hospital before ICU admission, diuresis, and GCS) and imbal-
ances with respect to the proportion of remission status and lower paO2 (see Table 1) are possi-
ble explanations, we cannot rule out the possibility that this prognostic index performs worse
in independent cohorts than in the training cohort, even with all available variables. Second,
only crude paO2 values and not the amount of oxygen support was available at the time of ICU
admission. Thus, the paO2:FiO2-ratio (ratio of paO2 to the fraction of inspired oxygen) was
not incorporated into the scores. Finally, due to an inverse correlation between hyperleukocy-
tosis and paO2, paO2 values in hyperleukocytic AML may be in spuriously low.[37] Peripheral
capillary oxygen saturation (SpO2) might reflect gas exchange in this constellation more
accurate.
Conclusions
Our study indicates promising survival rates for patients with AML requiring intensive care
treatment. Based on data from a large multicenter cohort, we identified and validated relevant
risk predictors, which provided a basis for two scores distinguishing between survival differ-
ences both in the ICU as well as after ICU discharge. However, while these scores might aid the
prognostication of patients with AML treated in the ICU, decisions about initiating or pursuing
intensive treatment must not rely solely on the results of these scores.
This study should encourage further prospective analyses.
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